Clarithromycin extended-release - Abbott Laboratories

Drug Profile

Clarithromycin extended-release - Abbott Laboratories

Alternative Names: BIAXIN XL; BIAXIN XL Filmtab; Clarithromycin controlled release - Abbott; Clarithromycin modified release - Abbott Laboratories; Klacid Uno; Klaricid XL

Latest Information Update: 16 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antibacterials; Macrolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 01 Dec 2015 Launched for Acute exacerbations of chronic bronchitis in Austria, Hungary (PO) before December 2015
  • 01 Dec 2015 Launched for Acute sinusitis in Hungary, Austria (PO) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top